, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).

Engers DW, Blobaum AL, Gogliotti RD, Cheung YY, Salovich JM, Garcia-Barrantes PM, Daniels JS, Morrison R, Jones CK, Soars MG, Zhuo X, Hurley J, Macor JE, Bronson JJ, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR
ACS Chem Neurosci. 2016 7 (9): 1192-200

PMID: 27075300 · PMCID: PMC5031509 · DOI:10.1021/acschemneuro.6b00035

The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson's disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506). We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a number of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group. VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclinical safety species.

MeSH Terms (11)

Allosteric Regulation Amides Animals Chromatography, High Pressure Liquid Excitatory Amino Acid Agents Humans Picolinic Acids Pyrazoles Pyridines Receptors, Metabotropic Glutamate Structure-Activity Relationship

Connections (1)

This publication is referenced by other Labnodes entities: